Exenatide: pharmacokinetics, clinical use, and future directions-Reference-Cited by-同舟云学术

Exenatide: pharmacokinetics, clinical use, and future directions

Published:2017-03-22 Issue:6 Volume:18 Page:555-571
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Knop Filip K.¹²³,Brønden Andreas¹²,Vilsbøll Tina¹²

Affiliation:

1. Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

2. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

3. The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Funder

AstraZeneca

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1282463

Reference83 articles.

1. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

2. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

3. BYDUREON (exenatide extended-release) for injectable suspension: US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.

4. BYETTA (exenatide) injection: US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.

5. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide GLP-1 receptor agonists: From injection to oral delivery strategies;Biochemical Pharmacology;2024-11

2. FRAP analysis of peptide diffusion in extracellular matrix mimetic hydrogels as an in vitro model for subcutaneous injection;International Journal of Pharmaceutics;2024-10

3. Computational peptide discovery with a genetic programming approach;Journal of Computer-Aided Molecular Design;2024-04-03

4. Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus;Exploration of Drug Science;2024-04-03

5. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress;Free Radical Biology and Medicine;2024-03